NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
ALX Oncology Holdings Inc. ALXO
8 fiscal years on record · USD · FY2025 reported · SEC filings only
$-101.7M
$-84.4M
Growth
—
Revenue, FY2025 · full 8-year series below
Revenue $M
Net income $M
FY2022 · Revenue 0.0 · Net income -123.5
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
—
Operating margin
Net margin
FY2020 · Operating -3694.0% · Net -3869.7%
ROE
FY2025 · ROE -145.7%
Each USD of equity lost 146 cents this year.
The 8-year record
8 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue $B | · | · | · | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Operating income $B | −0.1 | −0.1 | −0.2 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 |
| EBITDA $B | −0.1 | −0.1 | −0.2 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 |
| Income tax $B | 0.0 | 0.0 | 0.0 | 0.0 | −0.0 | 0.0 | 0.0 | 0.0 |
| Net income $B | −0.1 | −0.1 | −0.2 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 |
| EPS, diluted $ | −1.90 | −2.58 | −3.74 | −3.03 | −2.07 | −2.76 | −7.56 | −6.33 |
| Dividend / sh $ | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · |
| ROE % | −145.7 | −88.9 | −71.0 | −39.4 | −21.1 | −25.5 | · | · |
| Shares out B | 0.05 | 0.05 | 0.05 | 0.04 | 0.04 | 0.04 | 0.00 | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 30 reconciliationsAUDITED
Reconciled in 8 of 19 fiscal years. 46 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2018